Eribulin mesylate is currently indicated as a sequential monotherapy to be administered after two chemotherapeutic regimens, including anthracycline and taxane treatments, for treatment of metastatic breast cancer. | Phase II trial of eribulin mesylate as a firstor second-line treatment for locally advanced or metastatic breast cancer A multicenter single-arm trial